Form 4: CRISPR Therapeutics Executive James R. Kasinger Reports Stock Transactions
SEC Form 4 Filing
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reports the vesting and sale of common shares to cover tax obligations.
Summary
- On February 16, 2025, James R. Kasinger acquired 20,000 common shares through the vesting of restricted stock units.
- On February 18, 2025, he sold 9,595 common shares at $53.85 to cover tax withholding obligations related to the vesting of restricted stock units.
- Also on February 18, 2025, he acquired 3,825 common shares through the vesting of restricted stock units.
- On February 19, 2025, he sold 1,947 common shares at $52.8 to cover tax withholding obligations.
- Following these transactions, Kasinger directly owns 74,880 common shares and 3,825 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing primarily reports routine transactions related to executive compensation. There are no indications of significant positive or negative developments.
Positives
- The vesting of restricted stock units indicates that performance milestones or time-based vesting requirements have been met.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are related to equity compensation plans designed to align the interests of executives with those of shareholders.
Comparison to Industry Standards
- Equity compensation is a standard practice among publicly traded biotechnology companies like CRISPR Therapeutics to attract and retain talent.
- Companies such as Intellia Therapeutics (NTLA) and Editas Medicine (EDIT) also utilize restricted stock units as part of their compensation packages.
- The vesting schedules and tax withholding practices described in the filing are typical for RSU grants in the biotech industry.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they involve the sale of shares by an executive to cover tax obligations.
- The sales are mandated by the company's RSU Settlement Policy, ensuring compliance with tax regulations.
Key Dates
| Date | Description |
|---|---|
| August 16, 2022 | Restricted stock unit award granted with respect to 20,000 Common Shares, with 100% of the shares vesting on February 16, 2025. |
| February 18, 2022 | Restricted stock unit award granted with respect to 15,300 Common Shares, vesting in four equal installments on February 18, 2023, February 18, 2024, February 18, 2025, and February 18, 2026. |
| February 16, 2025 | Acquisition of 20,000 common shares through vesting of restricted stock units. |
| February 18, 2025 | Sale of 9,595 common shares at $53.85 and acquisition of 3,825 common shares through vesting of restricted stock units. |
| February 19, 2025 | Sale of 1,947 common shares at $52.8. |
Keywords
CRISPR Therapeutics, CRSP, Form 4, Insider Trading, James R. Kasinger, Restricted Stock Units, Common Shares, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.